Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives.

No abstract is available for this paper.

• Publication year

  2026

• Venue

  Journal of Translational Medicine

• Publication date

  2026-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s12967-026-07887-8PMID 41764546
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• TRAF2 Promotes Liver Fibrosis via Regulation of the HIF-1α/GLUT1-Mediated Glycolysis in Hepatic Stellate Cells

  2025cited by this paper
• Mitochondrial Metabolism in T-Cell Exhaustion

  2025cited by this paper
• Structure of human mitochondrial pyruvate carrier MPC1 and MPC2 complex

  2025cited by this paper
• Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy.

  2025cited by this paper
• Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.

  2025cited by this paper
• Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours

  2025cited by this paper
• CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors

  2025cited by this paper
• Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives

  2025cited by this paper
• Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review

  2025cited by this paper
• A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma

  2025cited by this paper
• Immunometabolism of regulatory T cells in cancer

  2025cited by this paper
• Application and prospects of genetic engineering in CAR-NK cell therapy

  2025cited by this paper
• Improved VPS4B O-GlcNAc modification triggers lipid droplets transferring from adipocytes to nasopharyngeal carcinoma cells

  2025cited by this paper
• Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

  2025cited by this paper
• Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy.

  2025cited by this paper
• Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives

  2025cited by this paper
• Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives

  2025cited by this paper
• HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy

  2025cited by this paper
• TCR-T cell therapy for solid tumors: challenges and emerging solutions

  2025cited by this paper
• IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment

  2025cited by this paper
• Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation

  2025cited by this paper
• Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma

  2025cited by this paper
• Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

  2025cited by this paper
• Obecabtagene Autoleucel: First Approval

  2025cited by this paper
• Sex‐related changes in lactate dehydrogenase A expression differently impact the immune response in melanoma

  2025cited by this paper
• Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy.

  2025cited by this paper
• Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors

  2025cited by this paper
• T Cell Glycoengineering to Modulate Immune‐Tumor Crosstalk: A Universal Non‐Genetic Strategy for Enhanced Tumor Immunotherapy

  2025cited by this paper
• CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity

  2025cited by this paper
• Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming

  2025cited by this paper
• Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment

  2024cited by this paper
• Targeting lipid metabolism of macrophages: A new strategy for tumor therapy

  2024cited by this paper
• Advances in reprogramming of energy metabolism in tumor T cells

  2024cited by this paper
• Breakthrough of solid tumor treatment: CAR-NK immunotherapy

  2024cited by this paper
• Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma

  2024cited by this paper
• Lactate and Lactylation: Dual Regulators of T-Cell-Mediated Tumor Immunity and Immunotherapy

  2024cited by this paper
• Exploring the potential of CAR-macrophage therapy.

  2024cited by this paper
• Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

  2024cited by this paper
• MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity

  2024cited by this paper
• HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells

  2024cited by this paper
• Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments

  2024cited by this paper
• Regulation of CD8+ T cells by lipid metabolism in cancer progression

  2024cited by this paper
• Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China’s responses to address secondary cancer risks of CAR-T therapy

  2024cited by this paper
• GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency

  2024cited by this paper
• NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors

  2024cited by this paper
• CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

  2024cited by this paper
• CAR T cell combination therapies to treat cancer.

  2024cited by this paper
• Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions

  2024cited by this paper
• Genetically engineering glycolysis in T cells increases their antitumor function

  2024cited by this paper
• Advances in CAR-T-cell therapy in T-cell malignancies

  2024cited by this paper
• Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control

  2024cited by this paper
• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

  2024cited by this paper
• Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy

  2024cited by this paper
• Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies

  2024cited by this paper
• Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation.

  2024cited by this paper
• Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting

  2024cited by this paper
• Prognostic Value of “Basal-like” Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer

  2024cited by this paper
• CRISPR–Cas9 applications in T cells and adoptive T cell therapies

  2024cited by this paper
• Targeting the Warburg Effect in Cancer: Where Do We Stand?

  2024cited by this paper
• Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation

  2024cited by this paper
• FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.

  2024cited by this paper
• World’s first TIL therapy approved

  2024cited by this paper
• Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment

  2024cited by this paper
• Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets

  2024cited by this paper
• Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

  2023cited by this paper
• Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions

  2023cited by this paper
• Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes

  2023cited by this paper
• SLC1A5, unrelated to prognosis, was associated with CD8+ T-cell exclusion in the tumor microenvironment of squamous cell carcinoma

  2023cited by this paper
• Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis

  2023cited by this paper
• Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers

  2023cited by this paper
• Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

  2023cited by this paper
• Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity.

  2023cited by this paper
• Modulation of T cells by tryptophan metabolites in the kynurenine pathway.

  2023cited by this paper
• Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy

  2023cited by this paper
• Beggars banquet: Metabolism in the tumor immune microenvironment and cancer therapy.

  2023cited by this paper
• Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies

  2023cited by this paper
• SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity

  2023cited by this paper
• Glutaminolysis and peripheral CD4+ T cell differentiation: from mechanism to intervention strategy

  2023cited by this paper
• Metabolism, metabolites, and macrophages in cancer

  2023cited by this paper
• Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α.

  2023cited by this paper
• Challenges and new technologies in adoptive cell therapy

  2023cited by this paper
• Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice

  2023cited by this paper
• NLGN4X TCR transgenic T cells to treat gliomas

  2023cited by this paper
• Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer

  2023cited by this paper
• Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

  2023cited by this paper
• Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy.

  2023cited by this paper
• Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation

  2023cited by this paper
• SCD1 inhibition enhances the effector functions of CD8 + T cells via ACAT1‐dependent reduction of esterified cholesterol

  2023cited by this paper
• Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming

  2023cited by this paper
• Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity

  2023cited by this paper
• The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors

  2023cited by this paper
• CAR-macrophage: An extensive immune enhancer to fight cancer

  2022cited by this paper
• Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor.

  2022cited by this paper
• Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment

  2022cited by this paper
• Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells

  2022cited by this paper
• CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro

  2022cited by this paper
• NKT cells adopt a glutamine-addicted phenotype to regulate their homeostasis and function

  2022cited by this paper
• Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy

  2022cited by this paper
• Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease

  2022cited by this paper
• Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

  2022cited by this paper

• No citing papers are available for this paper.